

1 **Title: Hydroxychloroquine pre-exposure prophylaxis to prevent SARS-CoV-2 among**
2 **health care workers at risk for SARS-CoV-2 exposure: A nonrandomized controlled trial**

3 Running Title: Hydroxychloroquine pre-exposure prophylaxis for SARS-CoV-2

4

5 Authors: Vanessa N. Raabe, MD¹; Andrew Fleming, MD^{1,2}; Marie I. Samanovic, Ph. D¹; Lilin
6 Lai, MD^{1,3}; Hayley M. Belli, Ph. D⁴; Mark J. Mulligan, MD¹; H. Michael Belmont, MD⁵

7

8 Affiliations:

9 ¹ Division of Infectious Diseases & Immunology and NYU Langone Vaccine Center, Department
10 of Medicine, New York University Grossman School of Medicine

11 ² Current affiliation: Division of Infectious Diseases & Immunology, Department of Medicine,
12 New York University Long Island School of Medicine

13 ³ Current affiliation: Emory Vaccine Center, Emory University School of Medicine

14 ⁴ Division of Biostatistics, Department of Population Health, New York University Grossman
15 School of Medicine

16 ⁵ Department of Rheumatology, Department of Medicine, New York University Grossman
17 School of Medicine

18

19 Corresponding Author: Vanessa Raabe, 430 E 29th St., Alexandria Center for Life Sciences West
20 Tower, 3rd Floor, New York, NY 10016. Vanessa.Raabe@nyulangone.org

21

22 World Count: Abstract – 274; Text - 3041

23 **Abstract:**

24 Background: Aerosol-generating procedures increase the risk of severe acute respiratory
25 syndrome coronavirus 2 (SARS-CoV-2) infection among health care workers (HCWs). An
26 effective pre-exposure prophylaxis would mitigate this risk.

27
28 Objective: To determine the efficacy of pre-exposure prophylactic hydroxychloroquine for the
29 prevention of SARS-CoV-2 infection and symptomatic coronavirus 19 disease (COVID-19)
30 among HCWs at high occupational risk of SARS-CoV-2 exposure.

31
32 Methods: 130 HCWs in the New York University Langone Health System (NYULHS) who
33 performed aerosol-generating procedures on patients with COVID-19 or provided bedside care
34 for inpatients with COVID-19 or persons with suspected COVID-19 in an emergency
35 department, for at least three shifts in a 7-day period, during the first 2020 COVID-19 wave in
36 New York City were enrolled. Participants elected to take oral hydroxychloroquine, 600 mg on
37 day 1 followed by 200 mg daily, or not take hydroxychloroquine for up to 90 days. Participants
38 self-collected dried blood spots and completed digital questionnaires regarding COVID-19
39 symptoms, adverse events, and other COVID-19 medication use.

40
41 Results: Six participants (7.5%) seroconverted during the trial: four who took
42 hydroxychloroquine (6.8%) and two who declined hydroxychloroquine (9.5%). All participants
43 not taking hydroxychloroquine reported COVID-19 symptoms at seroconversion compared to
44 one of four participants (25%) who took hydroxychloroquine. Adverse events occurred in eight
45 participants (9.6%) on hydroxychloroquine and were mostly mild.

46
47 Conclusions: This study (ClinicalTrials.gov NCT04354870) did not demonstrate a statistically
48 significant difference in SARS-CoV-2 seroconversion associated with hydroxychloroquine pre-
49 exposure prophylaxis among HCWs at high risk of occupational SARS-CoV-2 exposure,
50 although was underpowered and a high rate of hydroxychloroquine discontinuation was
51 observed.

52 **Introduction**

53 The coronavirus disease 19 (COVID-19) pandemic, caused by severe acute respiratory
54 syndrome coronavirus 2 (SARS-CoV-2), has led to over 530 million cases and over 6.2 million
55 deaths worldwide, including over 78 million cases and over 960,000 deaths in the United States.¹
56 The mainstay of SARS-CoV-2 prevention throughout the pandemic focused on infection control
57 measures, such as physical distancing, enhanced hand hygiene, and use of protective equipment.
58 The development and implementation of effective COVID-19 vaccines significantly advanced
59 COVID-19 prevention capacity, although breakthrough infections occur and vaccine rollout
60 worldwide has been hindered by vaccine hesitancy and/or supply and distribution challenges.
61 Multiple therapeutics exist for COVID-19, including immunomodulatory, antiviral, and
62 monoclonal antibody agents; however, only one monoclonal antibody (tixagevimib/cilgavimab)
63 is currently licensed as pre-exposure prophylaxis. Both the supply of tixagevimib/cilgavimab and
64 the population eligible to receive it are limited. Additional effective pre-exposure prophylactic
65 medications against SARS-CoV-2 would mitigate the risk of infection, especially if future
66 SARS-CoV-2 variants capable of eluding vaccine-induced immunity and escaping neutralization
67 by monoclonal antibodies become widespread. Effective pre-exposure prophylaxis would benefit
68 individuals at high risk of exposure or severe disease in addition to those with decreased vaccine
69 responsiveness.

70 Hydroxychloroquine is approved by the U.S. Food and Drug Administration for the
71 treatment and prevention of malaria and the treatment of rheumatoid arthritis, systemic lupus
72 erythematosus and chronic discoid lupus erythematosus. Interest in using hydroxychloroquine
73 for SARS-CoV-2 infection developed after hydroxychloroquine and its relative, chloroquine,
74 were demonstrated to inhibit SARS-CoV-2 *in vitro*.^{2,3} Multiple mechanisms for the inhibition of

75 SARS-CoV-2 by hydroxychloroquine have been proposed, including impairment of spike
76 protein binding to cellular gangliosides, blockade of virus transport from early endosomes to
77 lysosomes, and increased intraorganellar pH.^{2,4-7} Additionally, hydroxychloroquine has
78 immunomodulatory effects that could modify COVID-19 disease by dampening the
79 hyperinflammatory state induced by SARS-CoV-2 infection.^{7,8} The U.S. Food and Drug
80 administration issued an emergency use authorization (EUA) for hydroxychloroquine on 28
81 March 2020, but revoked the EUA on 15 June 2020 based on lack of clinical benefit during
82 treatment of patients hospitalized with COVID-19. The majority of studies of COVID-19
83 treatment with hydroxychloroquine, either alone or combined with azithromycin, have not
84 demonstrated improvement in clinical outcomes.⁹⁻¹⁹

85 *In vitro* studies demonstrate that inhibition of SARS-CoV-2 by hydroxychloroquine was
86 greater when the drug was added prior to viral infection compared to post-infection.³ This raised
87 questions as to whether hydroxychloroquine pre-exposure prophylaxis could decrease SARS-
88 CoV-2 infection. Clinical trials of hydroxychloroquine pre-exposure prophylaxis to date have not
89 demonstrated a difference in SARS-CoV-2 infection.²⁰⁻²² Here we present the results of a
90 nonrandomized, open-label clinical trial [Clinicaltrials.gov NCT04354870] of
91 hydroxychloroquine pre-exposure prophylaxis among health care workers (HCWs) at high risk
92 of occupational SARS-CoV-2 exposure in the New York University Langone Health System
93 (NYULHS) initiated during the first 2020 wave of the COVID-19 pandemic in New York City,
94 prior to COVID-19 vaccine availability, to determine the efficacy of pre-exposure prophylactic
95 hydroxychloroquine for the prevention of SARS-CoV-2 infection and symptomatic COVID-19.

96

97 **Methods**

98 *Study Design:* To evaluate whether hydroxychloroquine pre-exposure prophylaxis reduced the
99 incidence of SARS-CoV-2, we conducted a nonrandomized, open-label clinical trial
100 (ClinicalTrials.gov NCT04354870) among HCWs in the NYULHS. The primary outcome was
101 seroconversion to SARS-CoV-2. Secondary outcomes included COVID-19 illness severity,
102 incidence of symptomatic and asymptomatic SARS-CoV-2 infection, and hydroxychloroquine
103 tolerability/adverse events. All study visits occurred remotely due to the ongoing COVID-19
104 pandemic. Following a combined screening and enrollment visit, study visits were conducted
105 every 30 days (+/- 7 days) to complete four study visits. The study was reviewed and approved
106 by the New York University Grossman School of Medicine (NYUSOM) institutional review
107 board (IRB) prior to study initiation.

108
109 *Study Arm Assignments:* Participants chose whether they were included in the
110 hydroxychloroquine arm or no hydroxychloroquine arm of the study. Verbal assessment of
111 whether an eligible participant elected to take or declined hydroxychloroquine was obtained at
112 enrollment. Participants were allowed to switch between study arms by contacting the study team
113 or indicating a change in hydroxychloroquine use via digital questionnaire. Primary and
114 secondary outcome analyses were performed based on original study arm assignment using
115 Independent Samples T-test with Welch's correction (GraphPad Prism 9.2).

116
117 *Participants:* This study recruited adults ages 18 years and older employed as HCWs in the
118 NYULHS who provided informed consent for study participation and were involved in aerosol-
119 generating procedures on confirmed COVID-19 patients using appropriate personal protective
120 equipment (PPE), provided direct bedside care to confirmed COVID-19 patients using

121 appropriate PPE for three or more shifts in a 7-day period, and/or provided direct care to
122 suspected COVID-19 patients in the emergency department or another inpatient unit using
123 appropriate PPE for three or more shifts in a 7-day period. Participants were excluded from the
124 hydroxychloroquine arm if they had any of the following: diagnosed with COVID-19; known
125 hypersensitivity to hydroxychloroquine or chloroquine; stage 4 or higher chronic kidney disease,
126 retinal disease, congenital prolonged QTc interval syndrome, or torsade de pontes; or
127 concomitant use of amiodarone, digoxin, flecainide, procainamide, or propafenone.

128

129 *Sample Size:* An anticipated sample size of 350 participants was calculated to have 80% power
130 to detect a 15% difference in seroconversion between the study arms assuming a two-sided type I
131 error rate of 0.05 and a seroconversion rate of 35% in the no hydroxychloroquine arm. We did
132 not know in advance how many study participants would decide to take hydroxychloroquine, but
133 estimated two-thirds of participants would elect to take hydroxychloroquine.

134

135 *Informed Consent, Screening, and Demographics:* Interested individuals were prescreened by
136 telephone. Following prescreening, individuals who appeared eligible were emailed electronic
137 consent forms using the Research Electronic Data Capture (REDCap) system. A study
138 coordinator reviewed the electronic consent form with the participant by phone and answered
139 any questions about the study during the screening/enrollment visit. Participants consented via
140 electronic signature while in verbal communication with the study team, after which
141 demographics, employment information, and medical history were collected to verify eligibility.
142 Additional medication and symptom questionnaires were distributed to participants via REDCap.

143

144 *Hydroxychloroquine Dispensing:* Prescriptions for oral hydroxychloroquine tablets (600 mg on
145 day 1 followed by 200 mg daily thereafter) were provided to an NYU-based pharmacy which
146 dispensed the study medication from a dedicated study supply for participants who opted to take
147 hydroxychloroquine. Study medication was either picked up by participants in-person or mailed
148 directly to participants. 30-day prescriptions were prescribed and filled in a similar manner at
149 study day 30 and 60 for participants who remained in the hydroxychloroquine study arm.

150
151 *Digital Questionnaires:* Individualized links to online REDCap questionnaires were emailed to
152 participants at each study visit (screening/enrollment and days 30, 60, and 90 following
153 enrollment). Links provided access to questionnaires regarding any potential adverse events,
154 dried blood spot (DBS) card completion, medication use (hydroxychloroquine and concomitant
155 medications), and potential COVID-19 symptoms. Questionnaire responses were connected to
156 individual participants only by study-assigned identification numbers. Any participant reporting
157 a potential adverse event was subsequently contacted by a study investigator to collect additional
158 data.

159
160 *Dried Blood Spot Collection:* DBS cards were self-collected by participants at enrollment, and
161 days 30, 60, and 90 after enrollment. Participants were provided with four DBS collection kits
162 and written instructions for collecting and returning DBS cards via designated drop-off collection
163 boxes located at each participating NYULHS facility. Each collection kit contained: written
164 collection instructions, alcohol pads, lancets, gauze, bandages, pre-labeled DBS cards and
165 sealable foil bags containing desiccant, and envelopes for drop-off. In brief, participants were
166 instructed to wash their hands, clean the tip of their finger with an alcohol pad, and deploy a

167 contact-activated lancet to elicit a drop of blood. The first drop of blood was wiped away and
168 subsequent drops were lightly dabbed onto the DBS card until all five spots on the card were
169 filled, after which a bandage was applied to the finger. The DBS card was allowed to air dry at
170 room temperature for 3 hours and then sealed in the foil bag containing desiccant, which was
171 placed in a biosafety hazard-labeled envelope and deposited at one of the designated drop-off
172 sites within 2 weeks after collection.

173

174 *Dried Blood Spot Elution:* A 6 mm hole-puncher was used to remove dried blood spots from the
175 card. Each punched out spot was placed in a well of a 24-well plate containing 300 μ l phosphate-
176 buffered saline (PBS) with 0.05% Tween 20 (PBS-T) and 0.08% sodium azide and shaken for 4
177 hours at room temperature or overnight at 4°C. Eluates were transferred to microcentrifuge tubes
178 and centrifuged for 2 minutes at 10,500 g prior to use.

179

180 *Dried Blood Spot ELISA Validation:* IgM and IgG antibodies to SARS-CoV-2 S1 protein in sera
181 and DBS collected simultaneously from NYULHS employees with or without a known history
182 of SARS-CoV-2 infection, who provided informed consent to participant in a separate
183 NYUSOM IRB-approved protocol for healthy volunteers, were assessed using an in-house
184 developed SARS-CoV-2 S1 ELISA. Dried blood spots eluates and sera were heat inactivated at
185 56°C for 1 hour prior to use.

186

187 *SARS-CoV-2 S1 ELISA:* 96-well ELISA plates were coated with 1 μ g/ml SARS-CoV-2 S1
188 protein (Sino Biological Inc. 40591-V08H) diluted in PBS and incubated overnight at 4°C. Plates
189 were washed four times with PBS-T and blocked with PBS-T containing 4% non-fat milk and

190 5% whey for 1 hour prior to adding sera or DBS eluates. For DBS ELISA validation and
191 controls, sera samples were diluted to a 1:50 concentration while DBS eluates were not diluted.
192 Plates were washed four times with PBS-T after a 2-hour incubation period at room temperature.
193 Horseradish-peroxidase conjugated goat-anti human IgG and IgM (Southern BioTech 2040-05
194 and 2020-05) was added in 1:2000 and 1:1000 dilutions, respectively. After incubating for 1 hour
195 plates were washed four times with PBS-T and developed with TMB Peroxidase Substrate
196 3,3',5,5'-Tetramethylbenzidine (Thermo Scientific 34029) for 5 minutes, after which the reaction
197 was stopped with 1M sulfuric acid or 1N hydrochloric acid. The optical density (OD) was
198 determined by measuring the absorbance at 450 nm on a Synergy 4 (BioTek) plate reader. Heat-
199 inactivated pooled sera from hospitalized individuals with COVID-19 served as positive controls
200 and sera collected from healthy volunteers prior to the COVID-19 pandemic served as negative
201 controls. All control samples were obtained from research protocols approved by the NYUSOM
202 IRB.

203
204 *Role of the Funding Source:* New York University Langone Health System provided funding and
205 a dedicated hydroxychloroquine medication supply for the conduct of this study.

206

207 **Results**

208 *Trial Participation:* A total of 156 participants were screened for the trial, of which one hundred
209 and thirty participants enrolled between 29 April 2020–15 May 2020. Enrollment was closed on
210 21 July 2020 due to lack of further interest from potential participants. Eighty-three participants
211 elected to take hydroxychloroquine and 47 declined hydroxychloroquine (Figure 1). Participants
212 who elected to take hydroxychloroquine were more likely to be male ($p=0.02$) and had a median

213 older age ($p=0.001$) compared to participants who declined hydroxychloroquine (Table 1). No
214 significant differences in race ($p=0.91$) or ethnicity ($p=0.21$) were reported among individuals
215 who elected to take or declined hydroxychloroquine. Of the one hundred and thirty enrolled
216 participants, thirty-nine (30%) formally left the study, of which twenty-three (17.7%) were
217 participant-initiated and sixteen (12.3%) were withdrawn by study investigators. Only ten
218 participants (12%) who originally elected to take hydroxychloroquine remained on the
219 medication at day 90.

220
221 *DBS SARS-CoV-2 SI ELISA Validation:* Eighty-two participating NYULHS employees
222 consented to provide DBS samples from 27 March 2020–8 April 2020, forty with a previous
223 diagnosis of SARS-CoV-2 infection (“experienced”) and forty-two with no known history of
224 SARS-CoV-2 infection (“naive”). DBS ELISA data was normalized using a centering and
225 scaling-type approach where the IgG and IgM optical densities (ODs) were scaled using the
226 following formula: Scaled OD = $(OD - \text{average negative control}) / (\text{average positive control} -$
227 $\text{average negative control})$ (Figure 2). Binary cut-off thresholds for scaled ODs between the two
228 groups (SARS-CoV-2 “naive” and “experienced”) were identified at 0.61 for IgG and 0.49 for
229 IgM. A significant correlation between the experienced and naive groups ($p < 0.001$) for both
230 IgG and IgM was observed. Ten individuals from SARS-CoV-2 “naive” individuals tested
231 positive for IgG and/or IgM, of which nine consented to have subsequent sera samples drawn
232 which confirmed the presence of SARS-CoV-2 anti-spike antibodies (data not shown). On
233 further questioning, four of these nine (44.4%) individuals recalled potential COVID-19
234 symptoms. The 23.8% seropositivity observed among “naive” HCWs was consistent with 20%
235 seropositivity observed in New York City in April 2020.²³

236
237 *Seroconversion:* Seroconversion was defined as a new positive IgM and/or IgG scaled antibody
238 OD based on the binary cut-off criteria determined during ELISA validation. At least two DBS
239 cards, the minimum required to assess for seroconversion, were returned by eighty participants
240 (61.5%), fifty-nine of whom elected to take hydroxychloroquine (71.1%) and twenty-one of
241 whom declined hydroxychloroquine (44.7%). Scaled ODs for IgM and IgG antibodies at all
242 visits are shown in Figure 3. Six of the eighty participants (7.5%) who returned at least two DBS
243 cards had seroconversion based on scaled ODs for either IgM and/or IgG anti-SARS-CoV-2 S1
244 antibodies during the trial, four of fifty-nine (6.8%) who elected to take hydroxychloroquine and
245 two of twenty-one (9.5%) who declined hydroxychloroquine ($p=0.71$). Four participants (5%)
246 had seroconversion of IgM antibodies only, three of fifty-nine who took hydroxychloroquine
247 (5.1%) and one of twenty-one who declined hydroxychloroquine (4.8%). One participant in the
248 no hydroxychloroquine arm (4.8%) developed seroconversion of both IgM and IgG and one
249 participant on hydroxychloroquine (1.7%) developed only IgG seroconversion. Among the
250 ninety-one study participants who returned at least one DBS card, five (5.5%) participants, all of
251 which were in the hydroxychloroquine arm, had positive IgM or IgG ELISA results at study
252 entry indicating previous SARS-CoV-2 infection.

253
254 *COVID-19 Symptom Assessment:* At least one symptoms questionnaire was completed by one
255 hundred and twenty-five participants (96.2%) and symptom questionnaires were completed at all
256 four study time points by fifty-six participants (43.1%). Only one of four participants (25%) with
257 seroconversion in the hydroxychloroquine arm reported potential COVID-19 symptoms
258 (headache only) at the time of seroconversion. This compared to 100% ($n=2$, $p=0.26$) of

259 participants with seroconversion in the no hydroxychloroquine arm who reported potential
260 COVID-19 symptoms at the time of seroconversion: one who felt feverish and reported
261 nausea/vomiting and sore throat, and the other with fever, chills, myalgias, headache, anosmia,
262 cough, and shortness of breath. No participants were hospitalized or died during the study.

263
264 *Hydroxychloroquine Tolerability/Adverse Events:* Adverse events were more common among
265 participants originally assigned to the hydroxychloroquine arm [nine events among eight
266 participants [9.6%, 95% CI: 3.2%-16.1%]) compared to none in the no hydroxychloroquine arm.
267 The majority of adverse events were grade 1 (7 of 9, 77.8%) with one adverse event each with
268 grade 2 (diarrhea) and grade 3 severity (rash) [table 2]. Grade 1 events included appetite loss,
269 diarrhea, gastroesophageal reflux, gastrointestinal discomfort, hair loss, itching, and tinnitus.
270 Among participants taking hydroxychloroquine, eight adverse events (88.9%) were classified as
271 related to hydroxychloroquine use. Seven of the eight participants (87.5%) who experienced an
272 adverse event discontinued hydroxychloroquine. No serious adverse events were reported.

273

274 **Discussion**

275 Among health care workers at high risk of occupational SARS-CoV-2 exposure who
276 elected to take oral hydroxychloroquine, 600 mg once followed by 200 mg daily, for up to 90
277 days, we did not observe a statistically significant decrease in SARS-CoV-2 seroconversion
278 associated with hydroxychloroquine use. Study participants mostly identified as white and non-
279 Hispanic, limiting the generalizability of the study results to races and ethnicities identified at
280 higher risk for SARS-CoV-2 infection or disease.^{24, 25} However, these findings are consistent
281 with those observed among other trials of hydroxychloroquine pre-exposure prophylaxis for

282 HCWs and retrospective analyses of SARS-CoV-2 incidence among individuals taking
283 hydroxychloroquine for other medical conditions.^{20-22, 26-28}

284 Our methodology differed from previous studies in the dosing of hydroxychloroquine and
285 the use of dried blood spots to assess for seroconversion with an in-house developed SARS-
286 CoV-2 S1 ELISA. Dried blood spots were selected for use in this study due limitations in the
287 availability of commercial serological SARS-CoV-2 testing at the time of study initiation and to
288 facilitate self-collection of samples at home, thereby decreasing the risk of SARS-CoV-2
289 exposure by eliminating the need for travel to study visits. Although receipt of a COVID-19
290 vaccine could impact the interpretation of seroconversion of the S1 SARS-CoV-2 ELISA, this
291 would not have affected the outcomes of this study as it was conducted in its entirety in 2020
292 prior to the availability of COVID-19 vaccines to the NYULHS HCW population.

293 The incidence of adverse events in the hydroxychloroquine arm in this study (9.6% of
294 hydroxychloroquine users) was much lower than that reported (31%-45%) among other pre-
295 exposure prophylaxis studies of HCWs.²⁰⁻²² We do not anticipate the lower adverse event rate is
296 attributable to the dosing selected, but could be impacted by our high rates of
297 hydroxychloroquine discontinuation (88.0%) over the course of the study. We identify multiple
298 factors that may have contributed to the high rate of hydroxychloroquine discontinuation in this
299 study, including adverse events attributed to hydroxychloroquine, the U.S. Food and Drug
300 administration revoking the EUA for hydroxychloroquine for COVID-19 treatment,²⁹ and
301 negative media coverage of hydroxychloroquine during the study period.

302 This study has several limitations. The study was underpowered to detect the
303 effectiveness of hydroxychloroquine to reduce SARS-CoV-2 seroconversion. This study was
304 initiated in April 2020, during the peak of the first wave of the pandemic in New York City.³⁰

305 Initial estimates of anticipated seroconversion rates during the study period proved to be
306 overestimates as the incidence of new COVID-19 cases significantly declined in New York City
307 in May and June, 2020, and remained low for the remainder of the study period.³⁰ Adoption of
308 universal PPE use for all patient care encounters in the NYULHS during this period, including
309 fit-tested N95 masks or equivalent, may have contributed to lower than expected seroconversion
310 rates. Additionally, high rates of hydroxychloroquine discontinuation further decreased the
311 ability of the study to detect differences in seroconversion between hydroxychloroquine pre-
312 exposure prophylaxis users and non-users.

313

314 **Conclusions**

315 Although our study was underpowered, our results suggest that pre-exposure prophylaxis with
316 oral hydroxychloroquine, 600 mg once followed by 200 mg daily for up to 90 days, was safe but
317 did not reduce seroconversion to SARS-CoV-2 among health care workers at high risk of
318 occupational exposure to SARS-CoV-2 or reduce symptomatic presentation at the time of
319 seroconversion. Further adequately-powered randomized controlled trials in areas with high
320 SARS-CoV-2 circulation would be needed to adequately assess the effectiveness of off-label
321 hydroxychloroquine for the prevention of SARS-CoV-2 infection.

322

323 **Funding and Acknowledgements:**

324 The New York University Langone Health System provided funding for this study. This study
325 was conducted using clinical support provided the NYU-H+H Clinical and Translational Science
326 Institute (CTSI), which is supported by the National Center for Advancing Translational
327 Sciences (NCATS), National Institutes of Health, through Grant Award Number UL1TR001445.
328 We additionally wish to acknowledge technological support for electronic consenting for this
329 study provided by the NYU Division of Advanced Research Technologies and the NYULH
330 Office of Science and Research, as well as efforts provided by Marina Godina, Mahnoor Ali,
331 Laura Frye, Tori Rodrick, and Spandan Pandya.

332

333 **Conflicts of Interest Statement:** The authors report the following potential conflicts of interest:

334 MJM: Laboratory research and clinical trials contract funding for vaccines or monoclonal
335 antibodies to SARS-CoV-2 with Lilly, Pfizer, and Sanofi Pasteur; personal fees for Scientific
336 Advisory Board service from Merck & Co, Meissa Vaccines, Inc. and Pfizer.

337 VNR: Clinical trials contract funding for vaccines to SARS-CoV-2 with Sanofi Pasteur and
338 Pfizer. Laboratory research funding related to Ebola vaccine from Merck & Co.

339

340 **Data Sharing Statement**

341 Individual level data from participants will not be shared to protect the privacy of the
342 participating health care workers.

343 **References**

- 344 1. World Health Organization. WHO Coronavirus (COVID-19) Dashboard [Internet]. 2022
345 8 June. [cited 2022 8 June]. Available from <https://covid19.who.int/>.
- 346 2. Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS
347 coronavirus infection and spread. *Virol J.* 2005;2:69.
- 348 3. Yao X, Ye F, Zhang M, et al. In Vitro Antiviral Activity and Projection of Optimized
349 Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory
350 Syndrome Coronavirus 2 (SARS-CoV-2). *Clin Infect Dis.* 2020;71(15):732-9.
- 351 4. Fantini J, Di Scala C, Chahinian H, et al. Structural and molecular modelling studies
352 reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-
353 CoV-2 infection. *Int J Antimicrob Agents.* 2020;55(5):105960.
- 354 5. Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is
355 effective in inhibiting SARS-CoV-2 infection in vitro. *Cell Discov.* 2020;6:16.
- 356 6. Richard SA, Kampo S, Hechavarria ME, et al. Elucidating the Pivotal
357 Immunomodulatory and Anti-Inflammatory Potentials of Chloroquine and
358 Hydroxychloroquine. *J Immunol Res.* 2020;2020:4582612.
- 359 7. Vitte J, Michel M, Mezouar S, et al. Immune Modulation as a Therapeutic Option During
360 the SARS-CoV-2 Outbreak: The Case for Antimalarial Aminoquinolines. *Front*
361 *Immunol.* 2020;11:2159.
- 362 8. Lucchesi A, Silimbani P, Musuraca G, et al. Clinical and biological data on the use of
363 hydroxychloroquine against SARS-CoV-2 could support the role of the NLRP3
364 inflammasome in the pathogenesis of respiratory disease. *J Med Virol.* 2021;93(1):124-6.

- 365 9. Sivapalan P, Suppli Ulrik C, Sophie Lapperre T, et al. Azithromycin and
366 hydroxychloroquine in hospitalised patients with confirmed COVID-19-a randomised
367 double-blinded placebo-controlled trial. *Eur Respir J*. 2021.
- 368 10. Brown SM, Peltan I, Kumar N, et al. Hydroxychloroquine vs. Azithromycin for
369 Hospitalized Patients with COVID-19 (HAHPS): Results of a Randomized, Active
370 Comparator Trial. *Ann Am Thorac Soc*. 2020;18(4):590-7.
- 371 11. Schwartz I, Boesen ME, Cerchiaro G, et al. Assessing the efficacy and safety of
372 hydroxychloroquine as outpatient treatment of COVID-19: a randomized controlled trial.
373 *CMAJ Open*. 2021;9(2):E693-e702.
- 374 12. Sands K, Wenzel R, McLean L, et al. No clinical benefit in mortality associated with
375 hydroxychloroquine treatment in patients with COVID-19. *Int J Infect Dis*. 2021;104:34-
376 40.
- 377 13. Ulrich RJ, Troxel AB, Carmody E, et al. Treating COVID-19 With Hydroxychloroquine
378 (TEACH): A Multicenter, Double-Blind Randomized Controlled Trial in Hospitalized
379 Patients. *Open Forum Infect Dis*. 2020;7(10):ofaa446.
- 380 14. Geleris J, Sun Y, Platt J, et al. Observational Study of Hydroxychloroquine in
381 Hospitalized Patients with Covid-19. *N Engl J Med*. 2020;382(25):2411-8.
- 382 15. Ip A, Berry DA, Hansen E, et al. Hydroxychloroquine and tocilizumab therapy in
383 COVID-19 patients-An observational study. *PLoS One*. 2020;15(8):e0237693.
- 384 16. Magagnoli J, Narendran S, Pereira F, et al. Outcomes of Hydroxychloroquine Usage in
385 United States Veterans Hospitalized with COVID-19. *Med (N Y)*. 2020;1(1):114-27.e3.

- 386 17. Mahévas M, Tran VT, Roumier M, et al. Clinical efficacy of hydroxychloroquine in
387 patients with covid-19 pneumonia who require oxygen: observational comparative study
388 using routine care data. *Bmj*. 2020;369:m1844.
- 389 18. Rosenberg ES, Dufort EM, Udo T, et al. Association of Treatment With
390 Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With
391 COVID-19 in New York State. *Jama*. 2020;323(24):2493-502.
- 392 19. Self WH, Semler MW, Leither LM, et al. Effect of Hydroxychloroquine on Clinical
393 Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical
394 Trial. *Jama*. 2020;324(21):2165-76.
- 395 20. Abella BS, Jolkovsky EL, Biney BT, et al. Efficacy and Safety of Hydroxychloroquine vs
396 Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A
397 Randomized Clinical Trial. *JAMA Intern Med*. 2021;181(2):195-202.
- 398 21. Grau-Pujol B, Camprubí-Ferrer D, Marti-Soler H, et al. Pre-exposure prophylaxis with
399 hydroxychloroquine for COVID-19: a double-blind, placebo-controlled randomized
400 clinical trial. *Trials*. 2021;22(1):808.
- 401 22. Rajasingham R, Bangdiwala AS, Nicol MR, et al. Hydroxychloroquine as Pre-exposure
402 Prophylaxis for Coronavirus Disease 2019 (COVID-19) in Healthcare Workers: A
403 Randomized Trial. *Clin Infect Dis*. 2021;72(11):e835-e43.
- 404 23. Stadlbauer D, Tan J, Jiang K, et al. Repeated cross-sectional sero-monitoring of SARS-
405 CoV-2 in New York City. *Nature*. 2021;590(7844):146-50.
- 406 24. Hill L AS. COVID-19 Cases and Deaths by Race/Ethnicity: Current Data and Changes
407 Over Time [Internet]. Kaiser Family Foundation. 2022 Feb 22. [cited 2022 Mar 22].

- 408 Available from <https://www.kff.org/coronavirus-covid-19/issue-brief/covid-19-cases->
409 [and-deaths-by-race-ethnicity-current-data-and-changes-over-time/](https://www.kff.org/coronavirus-covid-19/issue-brief/covid-19-cases-and-deaths-by-race-ethnicity-current-data-and-changes-over-time/).
- 410 25. Stokes EK, Zambrano LD, Anderson KN, et al. Coronavirus disease 2019 case
411 surveillance - United States, January 22-May 30, 2020. *MMWR Morb Mortal Wkly Rep.*
412 2020;69(24):759-65.
- 413 26. Sjöwall J, Azharuddin M, Frodlund M, et al. SARS-CoV-2 Antibody Isotypes in
414 Systemic Lupus Erythematosus Patients Prior to Vaccination: Associations With Disease
415 Activity, Antinuclear Antibodies, and Immunomodulatory Drugs During the First Year of
416 the Pandemic. *Front Immunol.* 2021;12:724047.
- 417 27. Jung SY, Kim MS, Kim MC, et al. Effect of hydroxychloroquine pre-exposure on
418 infection with SARS-CoV-2 in rheumatic disease patients: a population-based cohort
419 study. *Clin Microbiol Infect.* 2021;27(4):611-7.
- 420 28. Macías J, González-Moreno P, Sánchez-García E, et al. Similar incidence of coronavirus
421 disease 2019 (COVID-19) in patients with rheumatic diseases with and without
422 hydroxychloroquine therapy. *PLoS One.* 2021;16(4):e0249036.
- 423 29. U.S. Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Revokes
424 Emergency Use Authorization for Chloroquine and Hydroxychloroquine [Internet]. 2021
425 26 November. [cited 2021 Nov 26]. Available from [https://www.fda.gov/news-](https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and)
426 [events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-](https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and)
427 [authorization-chloroquine-and](https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and).
- 428 30. NYC Health. COVID-19: Data [Internet]. 2021 26 November. [cited 2021 Nov 26].
429 Available from <https://www1.nyc.gov/site/doh/covid/covid-19-data-totals.page>.

430

431 Table 1: Enrolled Trial Participants According to Original Cohort Assignment by Age, Ethnicity,
 432 Gender, and Race

	Hydroxychloroquine (n = 83)	No hydroxychloroquine (n = 47)	All participants (n = 130)	P value
Number (%) by Gender				
Female	36 (43.4)	30 (63.8)	66 (50.8) ^a	0.02 ^b
Male	46 (55.4)	17 (36.2)	63 (48.5) ^a	
Other / Unknown	1 (1.2)	0 (0)	1 (0.8) ^a	
Median (IQR) ^c Age in Years	39 (33, 50)	32 (29, 38)	36 (31, 47)	0.001 ^d
Number (%) by Race				
American Indian/Alaska Native	0 (0)	0 (0)	0 (0)	0.91 ^e
Asian	13 (15.7)	9 (19.1)	22 (16.9)	
Black / African American	2 (2.4)	2 (4.3)	4 (3.1)	
Native Hawaiian / Pacific Islander	0 (0)	0 (0)	0 (0)	
White	58 (69.9)	34 (72.3)	92 (70.8)	
Other / Unknown	10 (12)	2 (4.3)	12 (9.2)	
Number (%) by Ethnicity				
Hispanic / Latinx	5 (6)	4 (8.5)	9 (6.9)	0.21 ^e
Non-Hispanic	59 (71.1)	38 (80.9)	97 (74.6)	
Unknown	19 (22.9)	5 (10.6)	24 (18.5)	

433 ^a Due to rounding, percentages do not add up precisely to 100%

434 ^b Independent Samples T-test

435 ^c Interquartile range

436 ^d Mann-Whitney U test

437 ^e Chi-squared test

438

439 Table 2: Adverse Events by Original Study Arm Assignment

MedDRA Term	HCQ Group	Control Group
	n=83 n (%)	n=47 n (%)
Appetite Loss	1 (1.2)	0 (0)
<i>Grade I</i>	1 (1.2)	0 (0)
<i>Grade II</i>	0 (0)	0 (0)
<i>Grade III</i>	0 (0)	0 (0)
<i>Serious Adverse Events</i>	0 (0)	0 (0)
Diarrhea	2 (2.4)	0 (0)
<i>Grade I</i>	1 (1.2)	0 (0)
<i>Grade II</i>	1 (1.2)	0 (0)
<i>Grade III</i>	0 (0)	0 (0)
<i>Serious Adverse Events</i>	0 (0)	0 (0)
Gastroesophageal Reflux	1 (1.2)	0 (0)
<i>Grade I</i>	1 (1.2)	0 (0)
<i>Grade II</i>	0 (0)	0 (0)
<i>Grade III</i>	0 (0)	0 (0)
<i>Serious Adverse Events</i>	0 (0)	0 (0)
Gastrointestinal discomfort	1 (1.2)	0 (0)
<i>Grade I</i>	1 (1.2)	0 (0)
<i>Grade II</i>	0 (0)	0 (0)
<i>Grade III</i>	0 (0)	0 (0)

<i>Serious Adverse Events</i>	0 (0)	0 (0)
Hair Loss	1 (1.2)	0 (0)
<i>Grade I</i>	1 (1.2)	0 (0)
<i>Grade II</i>	0 (0)	0 (0)
<i>Grade III</i>	0 (0)	0 (0)
<i>Serious Adverse Events</i>	0 (0)	0 (0)
Itching	1 (1.2)	0 (0)
<i>Grade I</i>	1 (1.2)	0 (0)
<i>Grade II</i>	0 (0)	0 (0)
<i>Grade III</i>	0 (0)	0 (0)
<i>Serious Adverse Events</i>	0 (0)	0 (0)
Rash	1 (1.2)	0 (0)
<i>Grade I</i>	0 (0)	0 (0)
<i>Grade II</i>	0 (0)	0 (0)
<i>Grade III</i>	1 (1.2)	0 (0)
<i>Serious Adverse Events</i>	0 (0)	0 (0)
Tinnitus	1 (1.2)	0 (0)
<i>Grade I</i>	1 (1.2)	0 (0)
<i>Grade II</i>	0 (0)	0 (0)
<i>Grade III</i>	0 (0)	0 (0)
<i>Serious Adverse Events</i>	0 (0)	0 (0)

440

441

442 **Figure Titles and Legends**

443 Figure 1 Title: Flow Diagram of Participants in the Hydroxychloroquine Pre-Exposure
444 Prophylaxis Study

445

446 Figure 2 Title: Dried Blood Spot ELISA Assay Validation — Scaled Optical Densities of Self-
447 Reported COVID-19 Experienced and Naïve Health Care Workers


448

449 Figure 2 Legend: These assays were performed during development of the DBS card antibody
450 elution procedure and ELISA. Health care workers who reported a previous history of COVID-
451 19 are shown as “experienced” blue squares, health care workers with no known history of
452 COVID-19 are shown as “naïve” yellow circles. Binary threshold cut-off values are indicated by
453 the dotted lines.


454

455 Figure 3 Title: Scaled Optical Densities from Dried Blood Spots According to Visit


456 Figure 3 Legend: Scaled optical densities from all returned dried blood spots from the enrollment
457 visit are shown as green circles (A), from the day 30 visit as blue upward triangles (B), from the
458 day 60 visit as purple downward triangles (C), and from the day 90 visit as red diamonds (D).
459 Values representing new seroconversions are indicated with an asterisk above the value. Binary
460 threshold cut-off values (established as in Figure 2) are indicated by the dotted lines.




Scaled Optical Densities of Self-Reported COVID-19 Experienced and Naive Health Care Workers




A Scaled Optical Densities from Visit 1 (Enrollment)



B Scaled Optical Densities from Visit 2 (Day 30)



C Scaled Optical Densities from Visit 3 (Day 60)



D Scaled Optical Densities from Visit 4 (Day 90)

